Form D · Biotechnology

PierianDx, Inc.

St. Louis, MO · CIK 0001730902

Offering snapshot reported Nov 9, 2021 · SEC filing

Reported sold
$17M
Offering amount: $17M
Investors reported
13
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Jun 23, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 9, 2021Initial$16,983,180No comparison13SEC filing
Nov 25, 2019Initial$21,870,702No comparison13SEC filing
Feb 12, 2018Initial$3,046,458No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$300K
Finders' fees
$0
Form D file number
021-420565

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Cowen and Company, LLC7616Cowen and Company, LLC · CRD 7616

Source: Form D, filed Nov 9, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Joseph Boorady Director
Charles Boorady Director
Barnard Buscemi Director
Chris Callahan Executive
Bryan Carey Director
Brian Carey Director
Frederick Hessler Director
Peter Jobse Director
Mark Mc Donough Director, Executive
Rakesh Nagarajan Director, Executive
Kerry Propper Director
Reid Robison Director
Michael Sanderson Director, Executive
James Starr Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6 Cityplace Drive Suite 550
St. Louis, MO, 63141